SCHEMBL2619224

SCHEMBL2619224

Cc1c[nH]c2ncncc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 1/20 0.45
LATS1 O95835 1/20 0.36
MET P08581 1/20 0.36
NTRK1 P04629 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
AXL P30530 1/20 0.35
PRKCI P41743 1/20 0.35
ROCK2 O75116 2/20 0.35
ROCK1 Q13464 1/20 0.35
CDC42BPB Q9Y5S2 1/20 0.35
TBK1 Q9UHD2 1/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
ATM Q13315 1/20 0.33
BTK Q06187 3/20 0.33
ITK Q08881 3/20 0.33
AKT1 P31749 2/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29598321 1.00 RPS6KA5 (0.45) RPS6KA5LATS1METNTRK1PRMT5
SCHEMBL14221256 0.85 RPS6KA5 (0.41) RPS6KA5LATS1METNTRK1PRMT5
SCHEMBL1093381 0.76 RPS6KA5 (0.43) RPS6KA5LATS1NTRK1ROCK2ROCK1
SCHEMBL23571474 0.75 RPS6KA5 (0.45) RPS6KA5LATS1NTRK1TBK1GSK3B
SCHEMBL6502791 0.75 RPS6KA5 (0.45) RPS6KA5LATS1METNTRK1PRMT5
SCHEMBL1085884 0.75 AXL (0.55) RPS6KA5LATS1NTRK1AXLPRKCI
SCHEMBL14237884 0.75 RPS6KA5 (0.45) RPS6KA5LATS1NTRK1TBK1GSK3B
SCHEMBL311676 0.75 RPS6KA5 (0.45) RPS6KA5LATS1NTRK1AXLROCK2
SCHEMBL21903027 0.75 RPS6KA5 (0.57) RPS6KA5LATS1NTRK1PRMT5WDR77
SCHEMBL13249593 0.75 RPS6KA5 (0.42) RPS6KA5LATS1AXLTBK1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
US-20230348852-A1 METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY NOVARTIS AG (CH) 2023-11-02 US disclosed
US-20230312565-A1 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2023-10-05 US disclosed
US-11739098-B2 Substituted indole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-29 US disclosed
WO-2023072301-A1 PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF 正大天晴药业集团股份有限公司 2023-05-04 WO disclosed
US-20230139171-A1 SYSTEM AND METHOD FOR INSTRUCTING ONE OR MORE WEATHER DRONES SITA INFORMATION NETWORKING COMPUTING UK LIMITED (GB) 2023-05-04 US disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-04-20 US disclosed
US-11420973-B2 Amide substituted indole compounds useful as TLR inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2022-08-23 US disclosed
WO-2022120118-A1 NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2022-06-09 WO disclosed
US-7846929-B2 Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents GENENTECH, INC. (US) 2010-12-07 US disclosed
WO-2010119264-A1 IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) 2010-10-21 WO disclosed
WO-2010052569-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2010-05-14 WO disclosed
WO-2010007114-A2 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-21 WO disclosed
WO-2010007116-A2 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-21 WO disclosed
US-20090118275-A1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-05-07 US disclosed
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PLRAMED LIMITED (GB) 2008-02-14 US disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
WO-2007022501-A2 USEFUL INDOLE COMPOUNDS MICROBIA, INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348852-A1 METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY B2M, EPAS1, LATS2 RPS6KA5 4091/4885LATS1 5/4885MET 523/4885
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PIK3CA, PI4KB, PI4KA RPS6KA5 515/4885LATS1 388/4885MET 1569/4885
US-11420973-B2 Amide substituted indole compounds useful as TLR inhibitors TLR9, TLR1, TLR7 RPS6KA5 1078/4885LATS1 3411/4885MET 1470/4885
US-20090118275-A1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PI4KB, PI4KA RPS6KA5 390/4885LATS1 561/4885MET 1674/4885
US-20230312565-A1 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS TLR9, TLR1, TLR7 RPS6KA5 2055/4885LATS1 3338/4885MET 313/4885
US-20070203209-A1 Useful indole compounds TPH2, HRH2, HRH1 RPS6KA5 1727/4885LATS1 1725/4885MET 4860/4885
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF RORC, RORB, RORA RPS6KA5 1043/4885LATS1 4164/4885MET 1192/4885
US-11739098-B2 Substituted indole compounds TLR7, TLR1, HTR7 RPS6KA5 794/4885LATS1 3021/4885MET 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.